The role of anti‐inflammatory adipokines in cardiometabolic disorders: Moving beyond adiponectin

Abstract

The global burden of obesity has multiplied owing to its rapidly growing prevalence and obesity‐related morbidity and mortality. In addition to the classic role of depositing extra energy, adipose tissue actively interferes with the metabolic balance by means of secreting bioactive compounds called adipokines. While most adipokines give rise to inflammatory conditions, the others with anti‐inflammatory properties have been the novel focus of attention for the amelioration of cardiometabolic complications. This review compiles the current evidence on the roles of anti‐inflammatory adipokines, namely, adiponectin, vaspin, the C1q/TNF‐related protein (CTRP) family, secreted frizzled‐related protein 5 (SFRP5), and omentin‐1 on cardiometabolic health. Further investigations on the mechanism of action and prospective human trials may pave the way to their clinical application as innovative biomarkers and therapeutic targets for cardiovascular and metabolic disorders.